Speakers

Conference Chair: Dr Phil Hammond

Conference Chair

Dr Phil Hammond

Dr Phil Hammond can talk seriously or humorously, and usually both, about any health and lifestyle topic. He has been an NHS doctor for 31 years, a comedian for 29 years, a BBC broadcaster for 28 years and Private Eye’s medical correspondent for 26 years. He qualified as a doctor in 1987, was a part time GP for 20 years, spent 5 years in sexual health and currently works in an NHS team helping young people with chronic fatigue. Phil presented five series of Trust Me, I’m a Doctor on BBC2, and has appeared many times on Have I Got News For You, the News Quiz, the Now Show and Countdown.

Phil has been a Lecturer in Medical Communication at the Universities of Birmingham and Bristol. As a journalist, he broke the story of the Bristol heart scandal in 1992, and gave evidence to the subsequent Public Inquiry. In 2012, Phil and Andrew Bousfield were shortlisted for the Martha Gellhorn Prize for investigative journalism for their Private Eye special report on the shocking treatment of NHS whistle-blowers, Shoot the Messenger. He has twice been named in the top 100 NHS Clinical Leaders by the Health Service Journal, and was voted Teacher of the Year by the medical students of Birmingham University.

Phil has presented his own BBC Radio Bristol show for 11 years, combining health, hope and happiness. With David Spicer, he has written 5 series of the medico-political satire ‘Polyoaks’ for Radio 4, and five books including ‘Staying Alive’ and ‘Sex, Sleep or Scrabble?.’ Phil was half of the award-winning comedy junior doctor double act Struck Off and Die with Tony Gardner, and has done four UK solo comedy tours, teaching audiences how to pleasure themselves sensibly and take the pressure off the NHS. His new show, ‘Happy Birthday NHS?’ celebrates its 70th birthday and provides a road map for its salvation. It tours in 2018.


 

Sir Andrew Dillon

Chair: On the front line of innovation - insights from the Cancer Drugs Fund and Early Access to Medicines Scheme

Sir Andrew Dillon
Chief Executive
NICE

Sir Andrew Dillon joined the NHS in 1975 and has held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George's Healthcare NHS Trust. He joined the National Institute for Health and Care Excellence as its founding Chief Executive in 1999.


 

Professor the Lord Darzi of Denham OM KBE PC FRS

Session: NICE futures

Professor the Lord Darzi of Denham OM KBE PC FRS

Professor Darzi is Director of the Institute of Global Health Innovation at Imperial College London. He also holds the Paul Hamlyn Chair of Surgery at Imperial College London and the Institute of Cancer Research, and is Executive Chair of the World Innovation Summit for Health in Qatar. He is a Consultant Surgeon at Imperial College Hospital NHS Trust and the Royal Marsden NHS Trust. 

Professor Darzi leads a large multidisciplinary team across a diverse and impactful portfolio of academic and policy research. His work drives the identification, development and adoption of innovation across international healthcare systems and champions high quality care. He has published over 1,000 peer-reviewed research papers to-date and has developed his status as a leading voice in the field of global health policy and innovation. In recognition of his achievements, Professor Darzi was elected a Fellow of the Academy of Medical Sciences, an Honorary Fellow of the Royal Academy of Engineering, a Fellow of the Royal Society and most recently, a foreign associate of the Institute of Medicine.

He was knighted for his services in medicine and surgery in 2002. In 2007, he was introduced to the United Kingdom’s House of Lords as Professor the Lord Darzi of Denham and appointed Parliamentary Under-Secretary of State at the Department of Health to lead a major review of the NHS, which culminated in the publication of his report, ‘High Quality Care for All: NHS Next Stage Review’, in 2008.  He revisited the report in 2018 publishing ‘Better Health and Care for All’.  He is currently a Non-Executive Director of NHS Improvement and was recently appointed Chair of the Accelerated Access Collaborative.

Professor Darzi has been a member of Her Majesty’s Most Honourable Privy Council since June 2009 and was awarded the Order of Merit by Her Majesty the Queen for exceptionally meritorious service towards the advancement of medicine in January 2016.

 


 

Professor Sir Simon Wessely

Session: Professor Sir Simon Wessely, Regius Professor of Psychiatry, King's College London in conversation with Phil Hammond

Professor Sir Simon Wessely
Professor of Psychological Medicine and Regius Professor of Psychiatry 
King's College London

Professor Sir Simon Wessely is Professor of Psychological Medicine and Regius Professor of Psychiatry at King’s College London and a Consultant Liaison Psychiatrist at King’s College and the Maudsley Hospitals. He is also past President of the Royal College of Psychiatrists.

His doctorate is in epidemiology, and he has over 700 original publications, with an emphasis on the boundaries of medicine and psychiatry, unexplained symptoms and syndromes, population reactions to adversity, military health, epidemiology and others.  He has co-authored books on chronic fatigue syndrome, randomised controlled trials and a history of military psychiatry. 

Professor Wessely is also President of the Royal Society of Medicine.

 

 

David Baghurst

Session: Faster to Market

David Baghurst
General manager
NIHR Office for Clinical Research Infrastructure (NOCRI) 

Dr David Baghurst has recently joined GMG as Director Research Programmes and is working with the RP and NOCRI teams. 

David has a DPhil in chemistry, MBA from Warwick and has worked as an academic (lecturer Imperial), industrial R&D manager (Cookson Group), business incubator developer and technology transfer manager (Oxford). David knows something about healthcare R&D, raising investment, business planning, IP, general management and doing business in Asia. 

He has been working with DH since 2009 and has been involved in several GMG tender exercises including the recent DH CCF and NOCRI retenders. 


 

 

Nicola Bent

Session chair: NICE guidelines and standards for quality improvement: planning ahead for use in practice

Nicola Bent
Programme Director, System Engagement
NICE

Nicola Bent is the Programme Director for System Engagement at NICE with responsibility for the Institute’s strategic engagement activities at a regional and local level. She also provides support for the NICE Implementation Strategy for NICE guidance, standards and advice.

Nicola is a registered member of the Royal Pharmaceutical Society of Great Britain and has a wealth of experience at a national, regional and local level having worked across the NHS for the past 20 years in a variety of roles.

 


 

Meindert Boysen

Session chair: Technology appraisals – fit for the future and Faster to Market

Meindert Boysen
Director, Centre for Health Technology Evaluation
NICE

Meindert is Director of the Centre for Health Technology Evaluation at the National Institute for Health and Care Excellence (NICE). He was previously responsible for running NICE’s technology appraisal and highly specialised technologies programmes, Meindert has a strong track record in health technology evaluation, occupying a senior technical and leadership role in NICE’s drug appraisal programme.

Before joining NICE in 2004 Meindert worked for Eli Lilly in the Netherlands, and for the King’s Fund in London after graduating with an MSc in Health Policy Planning and Financing from the London School of Economics & Political Sciences.

Meindert is currently on the Board of Directors for The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2017 – 2020 and is chair of the ISPOR Audit committee.


 

Sarah Byron

Session: NICE guidelines and standards for quality improvement: planning ahead for use in practice

Sarah Byron
Assistant Director, Diagnostics Assessment Programme
NICE

Biog to follow


 

 

Patrick Carey

Session: Beyond Brexit – UK medicines regulation, healthcare technology assessments and commissioning

Patrick Carey
Deputy Director, EU and International Team
Medicines and Healthcare Products Regulatory Agency

Patrick’s policy team lead on EU Exit for the regulation of medicines and medical devices, as well as the implementation of current EU regulations (such as the new EU Clinical Trials Regulation). Prior to joining the MHRA Patrick worked for the Secretary of State for Health, and has previously worked in management consultancy and school teaching.


 

 

Dr Paul Chrisp

Session: Too much medicine? – is over-prescription harming patients?

Dr Paul Chrisp
Director, Centre for Guidelines 
NICE

Paul has been with NICE since March 2009, where he was responsible for setting up the Institute’s accreditation programme for guideline developers, and more recently was Programme Director of the Medicines and Technologies Programme. Before joining NICE, Paul spent over 20 years in international medical publishing and communications, focusing on evidence to aid healthcare decision making and the adoption of new medicines. Paul trained as a pharmacist and is a member of the Royal Pharmaceutical Society.


 

Nick Crabb

Session: Beyond Brexit – UK medicines regulation, healthcare technology assessments and commissioning

Nick Crabb
Programme Director – Scientific Affairs
NICE

Nick had a 20 year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE as the associate director for the Diagnostics Assessment Programme in 2010. Nick was responsible for the establishment and management of the programme. In 2014 Nick was appointed Programme Director for Scientific Affairs where he oversees NICE Scientific Advice, the Science Policy and Research programme and the NICE Office for Market Access.


 

Shirley Cramer CBE

Session: NICE futures 

Shirley Cramer CBE
CEO
RSPH

Shirley has been the CEO of the Royal Society for Public Health since 2013. RSPH works across the UK and internationally to improve and protect the public’s health and wellbeing. She chairs the ‘People in UK Public Health’ advisory group, a cross government committee which advises on the future of the workforce for the public’s health and she is Vice Chair of the Public Health System Group in England. Prior to this she has been a CEO in education charities in both the USA and UK and a non – executive in the public and voluntary sectors. 

She is a member of the Global Advisory Board of the Robert Wood Johnson Foundation in the US and a Commissioner on the RSA Food, Farming and Countryside Commission. She chairs think tank, British Future and is a trustee of Alzheimer’s Research UK.

 

 

Blake Dark

Session: Technology appraisals – fit for the future

Blake Dark
NHS Commercial Medicines Director
NHS England

Biog to follow


 

 

Carla Deakin

Session: Technology appraisals – fit for the future

Carla Deakin
Programme Director, Commercial & Managed Access
NICE

Originally a NHS biomedical scientist, Carla spent 25 years in the UK Diagnostics industry gaining both commercial and healthcare system experience in a variety of roles for a major global healthcare company. During this time, Carla was an active contributor in the UK laboratory diagnostics industry and professional body arena, where she held a number of industry wide posts including chair of the Executive Board of BIVDA (British In-Vitro Diagnostics Association) 2012 – early 2014.

Carla joined NICE in February 2014 as Associate Director for the Diagnostics Assessment Programme, focusing in particular on raising the awareness of NICE’s diagnostics activities with external stakeholders. In 2017, Carla became Associate Director for the NICE Office for Market Access and the Accelerated Access Collaborative Secretariat before her move to the role of Programme Director for the newly established Commercial & Managed Access Programme in September 2018. Carla holds an MSc in Health Economics and Health Policy from the University of Birmingham and was previously a Fellow of Institute of Biomedical Sciences.


 

Dr Jennifer Dixon

Session: Towards a learning health care system: accelerating the uptake of innovation and best practice – Dr Jennifer Dixon, Chief Executive, Health Foundation
In conversation with Richard Vize

Dr Jennifer Dixon
Chief Executive
Health Foundation

Dr Jennifer Dixon joined the Health Foundation as Chief Executive in October 2013.

Jennifer was Chief Executive of the Nuffield Trust from 2008 to 2013. Prior to this, she was Director of Policy at The King’s Fund and was the policy advisor to the Chief Executive of the NHS between 1998 and 2000.

Originally trained in medicine, Jennifer practised mainly paediatric medicine prior to a career in policy analysis. She has undertaken research and written widely on health care reform both in the UK and internationally.

Jennifer has led two national inquiries for government: on the setting up of published ratings of quality of NHS and social care providers in England (2013); and on the setting up of ratings for general practices (2015). She was also a member of the Parliamentary Review Panel for the Welsh Assembly Government advising on the future strategy for the NHS and social care in Wales (2017-2018).

 


 

Professor Yvonne Doyle

Session: Prevention or pills?

Professor Yvonne Doyle
Regional Director London
Public Health England

Professor Yvonne Doyle joined PHE in December 2012. Yvonne Doyle qualified as a doctor and has worked in senior roles in the NHS and Department of Health, and in the academic and independent sectors. Since 2013 she provides leadership for health, prevention of ill health, health protection and reduction of inequalities at city-wide level to the population of London. Her recent international work on behalf of the Mayor of London has been to accelerate London’s ambition to become the healthiest and fairest global city. She has acted as an adviser to the WHO on Healthy Cities and has recently been appointed a Companion of the Order of the Bath for services to Public Health. As Regional Director for PHE London she ensures the quality, responsiveness and consistency of the services PHE centres provide. She also has an assurance role for emergency planning and response and is responsible for workforce development across the wider public health system.


 

Dr Samuel Finnikin

Session: Too much medicine? – is over-prescription harming patients?

Dr Samuel Finnikin
Institute of Applied Health Research, Clinical Research Fellow
University of Birmingham

Dr Finnikin is a GP in Sutton Coldfield and a researcher at the University of Birmingham. He is interested in how we can better use shared decision making in practice to reduce unwarranted variation and the harms of overmedicalisation. He is a member of the RCGP Preventing Overdiagnosis group and a fellow for Evidence and Values with the college.


 

Leslie Galloway

Session: Technology appraisals – fit for the future

Leslie Galloway
Chairman
Ethical Medicines Industry Group 

Leslie built a successful career over 40 years in senior management roles in both the pharmaceutical and medical device industries, culminating in the successful turnaround of a pharmaceutical business.

He was elected EMIG Chairman in 2005 and has been instrumental in the metamorphosis of EMIG from being a business/networking group to the influential trade association it is today. In 2005, EMIG began with 17 Member Companies and today, has 300+, of which, 90% choose to be represented only by EMIG. Consequently, EMIG represents c. 50% of UK branded medicines.

In July 2014, Leslie was elected VP, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He was Vice Chairman of the NICE Project Development Group for Local Formularies Good Practice Guidance, a member of the NICE Medicines Optimisation Guidance Development Group and is an Expert Adviser to the NICE Centre for Clinical Practice.

He was a member of the Accelerated Access Review Reference Group and a member of the Cancer Drugs Fund Working Group. He has published numerous articles, is a frequent speaker at national and international seminars, a Member of the Scottish Government’s Strategic Engagement Group, a Member of MENSA and is a visiting lecturer at the University of Cambridge.

 


 

Roz Gittins

Session: Driving quality improvement in care

Roz Gittins
Director of Pharmacy 
Addaction

Roz qualified as a Pharmacist in 2008 after graduating with a first class MPharm degree. She is the Director of Pharmacy for Addaction, a national third sector organisation. As the organisation’s professional lead for Pharmacy, she manages the National Medicines Management Team. She also holds the position of Medicines Safety Officer, Controlled Drug Accountable Officer and Responsible Person for Home Office licences. She has previously worked predominantly in NHS secondary care services and has undertaken various post graduate qualifications, specialising in psychiatry and substance misuse.
 
Roz is currently the Registrar for the College of Mental Health Pharmacy and a credentialed member. She is an accredited RCGP trainer for their Drug and Alcohol Certificates and occasionally locums in community pharmacies. She is an independent non-medical prescriber specialising in substance misuse, has contributed to CPPE publications and reviewed text book chapters on substance misuse for Oxford University Press. Roz has worked as a Consultant for the Choice and Medication website and is on the Editorial Board of Clinical Pharmacist.
 
Roz has been a pharmacist topic expert for NICE, and is now serving a three year term as an expert advisor. As a NICE scholar, she’ll be focusing on medicines optimisation in opioid substitute treatment, to help us and Addaction to continue to improve the quality of care delivery in substance misuse services.

 

 

Professor Carl Heneghan

Session: Reliable evidence?: The roles of real-world data, patient evidence and randomised trials in judging treatment effectiveness

Professor Carl Heneghan
Directot, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences
University of Oxford

Biog to follow


 

 

Louise Houson

Session: Prevention or pills?

Louise Houson
MD UK and Ireland
MSD

Louise Houson is the Managing Director of MSD in the UK, having taken up her position from September 2016. Louise brings to the role over 20 years of experience in the industry in a variety of commercial roles.

In her current role, Louise is a Board member of the ABPI (Association of the British Pharmaceutical Industry) and led the recent renegotiation of the Voluntary Pricing and Access scheme on behalf of the branded medicines industry.

Louise joined MSD in 1997 following a Masters degree in Biological Sciences from Oxford University. Outside of work she enjoys spending time with her family.


 

 

Dr Asma Khalil

Session: There’s an NHS approved app for that: the journey from digital concept to deployment

Dr Asma Khalil
Consultant Obstetrician
St George’s Hospital London

Biog to follow


 

 

Emily Lam

Session: Reliable evidence?: The roles of real-world data, patient evidence and randomised trials in judging treatment effectiveness

Emily Lam
Lay member, Guidelines Committee}
NICE

I have been supporting public and patient involvement in NICE guideline developments for a number of years. I am passionate about the potential contributions of patients and carers by taking an active role in sharing healthcare that affect them personally, and making an input in shaping research, as appropriate. This I believe is becoming ever moreimportant in the context of our ageing population as demand is growing and threatening to outstrip resources. Public and patient's active participation in healthcare is a mutually beneficial process, on one hand this would empower patients and carers so that they increase their confidence and expertise in optimising patient outcomes in the community. On the other hand, the interested, participating patient is more likely to be working collaboratively with the clinical professionals towards treatment goals. Subsequently, less waste in resources and more cost effective care should result, helping the NHS to be sustainable. For the above reasons I would definitely continue to be involved and contribute what I can to the process for some time yet.


 

Professor Gill Leng

Session: Effectiveness and affordability: national and global futures
Session chair: Driving quality improvement in care

Professor Gill Leng
Deputy Chief Executive and Health and Social Care Director 
NICE

Professor Gillian Leng is the Deputy Chief Executive at NICE, the Director of Health and Social Care, and a visiting professor at King's College London.

Gillian trained in medicine at Leeds, and then spent several years researching the epidemiology of peripheral vascular disease at Edinburgh University. She was involved in the Cochrane Collaboration as it first became established,and still contributes as an editor to the EPOC Group (Effective Practice and Organisation of Care). She specialised in public health medicine, and worked as a consultant before moving to NICE in 2001.

At NICE, Gillian has been responsible for the initial set up and running of the clinical guidelines programme, for establishing the NICE implementation function, and for setting up NHS Evidence. More recently she has been responsible for the transfer of the National Prescribing Centre into NICE, for establishing the NICE accreditation programme, and for new work on Quality Standards across health and social care.

Gillian is also Director of the Health and Social Care Programme and since January 2015 is leading the public health team at NICE.


 

Professor Carole Longson

Session: Faster to Market

Professor Carole Longson
Chief Scientific Officer
ABPI

Carole has a doctorate in Pharmacology, spending 8 years in drug discovery at GlaxoSmithKline on the identification and development of novel pharmaceuticals across multiple therapeutic areas.

A past president of Health Technology Assessment International, Carole has contributed to many international science and policy forums, including WHO advisory groups on Priority Medical Devices and

Innovative Technologies. Carole is a past member of the scientific committee of the European Commission Innovative Medicines Initiative and is Vice Chair of the Innovate UK Medicines Discovery Catapult.


 

Eric Low

Session: NICE futures

Eric Low
Senior Visiting Research Fellow, Leeds Institute of Clinical Trials Research, and former CEO, Myeloma UK

Biog to follow


 

 

Mirella Marlow

Session chair: The long term plan for life sciences: managing the innovation pipeline

Mirella Marlow
Programme Director, Centre for Health Technology Evaluation
NICE

Mirella Marlow is responsible for NICE’s programmes that evaluate and develop guidance on medical devices, diagnostics and interventional procedures.  She works with industry, health services, government policymakers, life sciences organisations and researchers to maximise the effectiveness of NICE’s work in these areas.   Mirella joined NICE in 2004, having previously worked for 15 years as a commissioner in the NHS. She has an MBA and a Masters in Medical Ethics and Law from Keele University. Her interests in medical ethics include measuring cost-effectiveness of interventions to improve safety in healthcare, and incorporating ethical considerations into HTA. 


 

Graham Martin

Session: Driving quality improvement in care

Graham Martin
Director of Research
THIS Institute

Graham Martin is Director of Research for THIS Institute, a new unit funded by the Health Foundation at the University of Cambridge to develop the evidence base for and impact of work to improve healthcare quality and safety, and Professor of Health Organisation and Policy in the SAPPHIRE Group, University of Leicester. His research focuses on social, organisational and professional issues in healthcare system change, with a particular focus on quality improvement work and policy initiatives to address quality, safety and risk in the NHS.


 

Professor John Mattick

Session: Bringing genomics to the clinical frontline

John Mattick AO FAA FTSE FAHMS HonFRCPA
Chief Executive
Genomics England

John Mattick is the Chief Executive of Genomics England. He was previously Director of the Garvan Institute of Medical Research in Sydney, where he established one of the first clinically accredited genome analysis enterprises.

He was a member of the Australian Health Ethics Committee, where he was involved in the development of the National Statement on the Ethical Conduct of Research involving Humans, and the Australian Law Reform Commission Report into the Protection of Human Genetic Information. Inter alia, he has also been a member of the Council of Scientists of the Human Frontier Science Program, a member of the Council of the Human Genome Organisation and Chair of several Genome Canada competitions and reviews.  

 


 

Deborah O'Callaghan

Session: NICE guidelines and standards for quality improvement: planning ahead for use in practice

Deborah O'Callaghan
Implementation consultant
NICE

Biog to follow


 

 

Neelam Patel

Session: There’s an NHS approved app for that: the journey from digital concept to deployment

Neelam Patel
Chief Operating Officer
MedCity

Neelam is COO of MedCity, a small organisation set up to support the growth of the life sciences sector within the Greater South East of England. Neelam supports the CEO and Board in driving the strategic direction of the group as well as being the lead advisor for clinical trials and supporting companies to connect to the right expertise and infrastructure to grow.  Neelam also supports DigitalHealth.London (of which MedCity is a founding partner) and its Accelerator, to simplify the landscape for digital health innovators in generating evidence.

Neelam has had a number of leadership roles in Pharma and she has used her industry experience to lead and progress projects in the not-for-profit sector as well as the National Institute of Health Research.

 


 

Dr Steven Pearson

Session: Effectiveness and affordability: national and global futures

Dr Steven Pearson
President
Institute for Clinical and Economic Review (ICER)

Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations to encourage collaborative efforts to improve patient care and control costs.  Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to inform policymakers and guide price and coverage negotiation. Dr. Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. 


 

Nina Pinwill

Session: Beyond Brexit – UK medicines regulation, healthcare technology assessments and commissioning

Nina Pinwill
Programme Director, System Engagement National Operational Lead, Cancer Drugs Fund
NHS England

As Head of Commercial Operations, Nina Pinwill leads the commercial planning and the Cancer Drugs Fund (CDF) at NHS England. Nina’s role is to ensure that patients have faster access to the most promising new treatments, taxpayers get better value for money in drug expenditure and the route to funding is speeded up for responsibly priced, promising drugs. Nina’s role also includes responsibility for patient access schemes (PAS), the Blueteq prior approval system and dose banding.

Nina received her first degree in Geography in 1995 and spent the next five years in various management and planning roles in the Lord Chancellors Department (now the Ministry of Justice). Nina then spent the next 16 years working at the National Institute for Health and Care Excellence (NICE).

In 2015 Nina was seconded to the Office for Life Sciences to work on the Accelerated Access Review.

Nina gained her MSc in Health Policy from Imperial College London in May 2016 and is a trustee for the Waldenström's Macroglobulinemia UK charity.

 


 

Dr Roshelle Ramkisson

Session: Driving quality improvement in care

Dr Roshelle Ramkisson,
Psychiatry Programme Director, North West
Health Education England

Biog to follow


 

 

Imelda Redmond

Session: Too much medicine? – is over-prescription harming patients?

Imelda Redmond
National Director
Healthwatch England.

Biog to follow


 

 

Dr Samantha Roberts

Session: The long term plan for life sciences: managing the innovation pipeline

Dr Samantha Roberts
Director of Innovation, Research and Life Sciences Group
NHS England

Samantha Roberts has recently been appointed as NHS England's Director of Innovation and Life Sciences.

She originally trained as a doctor and practiced medicine in South Africa, the UK, and Australia before joining McKinsey and Company where she worked in a wide range of industries before specialising in healthcare.

After McKinsey she moved into the NHS as a senior manager at a large teaching hospital in London (UCLH) and a director in an Academic Health Sciences Centre and Network (UCLPartners).

Over the last five years she has become involved in research, working with health economic models to inform evidence-based policy, initially at the London School of Economics before moving to the University of Oxford to undertake a DPhil (PhD).

 


 

Mark Salmon

Session: There’s an NHS approved app for that: the journey from digital concept to deployment

Mark Salmon
Programme Director Information Resources
NICE

Biog to follow


 

 

Michael Seres

Session: Faster to Market

Michael Seres
Founder
11Health

Biog to follow


 

 

Dr Jayne Spink

Session: Bringing genomics to the clinical frontline

Dr Jayne Spink
CEO
Genetic Alliance UK

Jayne has more than a decade’s experience in the third sector (former CEO of the Tuberous Sclerosis Association and Director of Policy & Research with the Multiple Sclerosis Society. She has a BSc and PhD in Genetics with postdoctoral research experience. After leaving the bench, Jayne worked for the Department of Health in Clinical Quality, Ethics and Genetics and has served as an Associate Director for the Centre for Clinical Practice at NICE.

Jayne joined Genetic Alliance UK in April 2017, a UK charity and umbrella group comprised of 200 third sector organisations, that variously provide support, information and funding for research. Genetic Alliance UK is home to Rare Diseases UK which campaigns on behalf of all those affected by Rare Conditions, and SWAN UK, providing support to families affected by “syndromes without a name” which are of likely genetic origin.

 


 

Alexia Tonnel

Session chair: There’s an NHS approved app for that: the journey from digital concept to deployment

Alexia Tonnel
Director of Evidence Resources

NICE

Alexia Tonnel is the director of Evidence Resources at NICE. She leads NICE’s digital services team as well as its information services function.

Alexia studied business and management in France after which she completed a Master of Science in International Accounting and Finance at the London School of Economics and Political Science.

Before joining NICE, Alexia was a Director with Deloitte in London where she advised a range of clients in the healthcare and life science industries on policy and strategy development as well as large programme implementation.

 


 

Dr Julian Treadwell

Session: Effectiveness and affordability: national and global futures

Dr Julian Treadwell
GP and Chair of the NICE Connect-Pathways Committee and Co-moderator for the NICE GP reference panel

Julian Treadwell  is a GP and is Chair of the NICE Connect-Pathways Committee and Co-moderator for the NICE GP reference panel.

He is also an NIHR Doctoral Research Fellow at the Nuffield Department of Primary Health Care Sciences in Oxford, researching novel ways to communicate clinical evidence to GPs.

 


 

Richard Vize

Conference chair

Richard Vize
Director
Public Policy Media Ltd

Richard Vize (@RichardVize) has been a commentator on public policy and public services reform for over 25 years. He is a columnist for the Guardian Healthcare Network, contributes to the British Medical Journal and works with a range of organisations across health and local government.

Richard is a former editor of both Health Service Journal and Local Government Chronicle, and was head of communications at regulator Ofsted. He and his teams have won a number of awards.

He is a trustee of the whistleblowing charity Public Concern at Work. Richard’s passions are photography, independent travel and political history.


Sheryl Warttig

Session: The long term plan for life sciences: managing the innovation pipeline

Sheryl Warttig 
Senior Technical Adviser – Centre for Health Technology 
NICE

Sheryl Warttig is a senior technical adviser in NICE’s Centre for Health Technology Evaluation. Sheryl is leading the delivery of HealthTech Connect- a national, systematic approach for identifying and supporting health technologies including devices, diagnostics, apps, and wearables. HealthTech Connect will be used by NICE, NHS England, and other UK healthcare decision makers as a fundamental component of topic selection processes.

Sheryl is also responsible for company engagement in the NICE Medical Technologies Evaluation Programme (MTEP). MTEP considers innovative medical technologies for the development of NICE guidance, and Medtech Innovation Briefings (NICE advice). At October 2018, the outputs include over 68 pieces of NICE guidance and over 156 pieces of NICE advice.

Sheryl joined NICE in 2011 after having previously worked in the NHS.  Sheryl has also worked in the NICE Clinical Guidelines Programme and the NICE Safe Staffing Programme.